TNNI3 and cancer: For these individuals, preemptive initiation of such therapies upon detection of early subclinical markers (e.g., a drop in LVGLS or rise in hs-cTnI) could mitigate or prevent irreversible cardiac damage, thereby allowing the safe continuation of essential cancer treatment (34, 35).